Topic: Triple-Negative Breast Cancer: From Mechanisms to Translational Frontiers

Triple-negative breast cancers are invasive breast cancers that are negative for estrogen receptors, progesterone receptors, and receptors for human epidermal growth factor receptor 2 (HER2).  Triple-negative breast cancers account for approximately 10-15% of all breast cancers.  Triple-negative breast cancers tend to be more common in younger women (less than age 40 years), Black women, and women with BRCA1 mutations.  In addition, triple-negative breast cancers tend to be aggressive, growing quickly and spreading faster than other types of breast cancer. Also, triple-negative breast cancer is more likely to recur after treatment when compared to other types of breast cancer.  Survival rates for triple-negative breast cancer tend to be lower than for other types of breast cancer.  Recent research has broadened our understanding of triple-negative breast cancer, including the epidemiology, the histopathology, and the treatment approaches. This issue focuses on triple-negative breast cancer, examining the underlying mechanisms and exploring current translational frontiers.

We invite research articles and reviews that explore topics including, but not limited to:

1. Molecular subtyping and heterogeneity of TNBC;

2. Tumor immune microenvironment and immunotherapy responsiveness;

3. Predictive biomarkers for treatment selection (e.g., TILs, PD-L1, BRCA/HRD);

4. Immune checkpoint inhibitors and combination strategies;

5. ADCs and other targeted therapies (e.g., sacituzumab govitecan, datopotamab deruxtecan);

6. ctDNA and liquid biopsy in TNBC diagnosis, MRD monitoring, and recurrence prediction;

7. Mechanisms of drug resistance and therapeutic evasion;

8. Single-cell and spatial transcriptomics in TNBC research;

9. Translational clinical trials and real-world evidence studies.

Triple-negative breast cancer，Estrogen receptor，Progesterone receptor，Human epidermal growth factor receptor 2 (HER2)